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of EGFR mutations in daily practice in advanced
NSCLC patients selected according to the ESMO
guideline: a large Caucasian cohort study
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Sara Vander Borght3, Kris Nackaerts1,2, Isabelle Wauters1 and Johan Vansteenkiste1,2*Abstract
Background: ESMO consensus recommends EGFR mutation testing in never/former light smokers (<15 pack-years)
or patients with non-squamous NSCLC. The aim of this work was to determine the frequency and clinical predictors
of EGFR mutations, and the role of specimen sampling tests, in Caucasian standard practice setting.
Methods: We screened 297 patients according to this consensus. Mutational analysis of EGFR was performed using
the Therascreen EGFR RGQ PCR mutation kit. Clinical and pathological correlative data were collected.
Results: An EGFR activating mutation was found in 32 patients (11%), twelve exon 19 deletions, two exon 18 and
eighteen exon 21 point mutations. Most were in females, but half were in smokers. Negative TTF-1 staining had a
very strong negative predictive value (all except one patient had TTF-1 positive adenocarcinoma). Both biopsies as
well as cytology specimens (mainly EBUS-TBNA) did well: 24 mutations in 213 biopsy samples (11.2%) and 8 in 84
cytology samples (9.5%), respectively. The Therascreen acted as a sensitive test in all types of samples: 7 activating
mutations were found in samples rated to have <5% of tumour cells, and there were only 4 test failures in the
whole series.
Conclusion: In this Caucasian standard practice NSCLC cohort, tested according to the ESMO consensus, activating
EGFR mutation occurred in 11% of the patients. Half of these were in former/current smokers. With our sampling
technique and use of the Therascreen kit, EBUS-TBNA cell blocks performed as good as biopsies.
Keywords: Predictive factors; Real-time quantitative polymerase chain reaction (rt-qPCR); EGFR mutation;
Endobronchial ultrasound; Biopsy methodsBackground
About 85% of all lung cancer patients have non-small
cell lung cancer (NSCLC), and the majority presents
with advanced stage disease at the time of diagnosis. The
standard of care for these patients is platinum-based
doublet chemotherapy [1]. This ‘any platinum doublet fits
all’ strategy results in a median overall survival of 8 to
10 months and a 1 year survival rate of about 33%.* Correspondence: johan.vansteenkiste@uzleuven.be
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in any medium, provided the original work is pDifferent strategies to prolong survival have been
developed. Besides customisation of chemotherapy accord-
ing to histological subtype [2], and the use of maintenance
therapy in order to achieve prolonged tumour control
[3], the most important change during the last decade
was the introduction of treatment guided by the tumour’s
genetic profile.
The epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) heralded this evolution, when
very pronounced and durable responses to these agents
were noted early in this century [4]. A few years later,
somatic mutations in the EGFR gene were discovered in
these highly responsive tumours. They affect the tyrosinean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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21 – and lead to constitutive activation of the receptor,
independent of ligand binding. The tumour becomes
highly dependent on this pathway, and thus very sensitive
to blockade of this pathway by TKIs [5]. Recent rando-
mised trials demonstrated that the presence of an EGFR
activating mutation was the best predictive factor for
response and progression-free survival (PFS) to EGFR TKIs
when compared to platinum doublet chemotherapy in the
first-line therapy of advanced NSCLC [6,7]. Given this
strong benefit of EGFR-TKIs in patients with a tumour
with an EGFR activating mutation (EGFR mut + tumour),
molecular profiling became necessary in the assessment of
stage IV NSCLC.
EGFR mutations are known to be associated with clin-
ical characteristics such as never-smoking status, female
gender, adenocarcinoma histology and South-East Asian
ethnicity [8]. Adenocarcinoma is by far the most common
NSCLC histology in South-East Asia, and about 40% of
these tumours are EGFR mutant [9]. The EGFR mutation
occurrence is much lower in Caucasian populations. As
both gefitinib and erlotinib are now registered in Europe
for the treatment of patients with an EGFR mut + tumour,
selection criteria to identify which patients are most likely
to have an EGFR mutation are needed. Based on the
South-Asian experience and the occurrence of the different
NSCLC histologies in Europe, a European guideline (ESMO
consensus [1]) recommends EGFR mutation testing in
never-/former light (<15 pack-years) smokers or patients
with non-squamous NSCLC.
As a consequence and in contrast with 10 years ago,
precise histological subtyping and EGFR testing is now
mandatory. Many colleagues of the multidisciplinary
team involved in the diagnostic flow of NSCLC – pul-
monologists, surgeons and radiologists – need to optimise
biopsy samples (size, content of tumour cells).
Until now, the most common diagnostic procedure for
the diagnosis of NSCLC was bronchoscopy, which may
however not always provide enough tissue for molecular
analysis. We therefore evaluated the performance of
different small tissue samples obtained during bron-
choscopic procedures, such as bronchial biopsies and
endobronchial ultrasound guided transbronchial needle
aspirations (EBUS-TBNA), in the molecular diagnostic
setting of NSCLC. Study aims were (1) the frequency of
EGFR mutations (exon 18–21) in a large Caucasian cohort;
(2) clinical and pathological predictors; (3) the sensitivity of
the Therascreen kit; and (4) the performance of cytology
versus biopsy samples for mutation analyses.
Methods
Study subjects
All consecutive EGFR mutation analysis reports in the
period from September 2010 until December 2011included were retrieved from the molecular genetics
database. During this period, our local policy was to
order EGFR mutation testing in all patients diagnosed
with advanced NSCLC, either of adenocarcinomas or
not-otherwise specified (NOS) histology, irrespective of
smoking history, or in those rare patients with squamous
cell carcinoma with a negative or light (<15 pack years)
smoking history.
Methods
The clinical data of the patients were retrieved retro-
spectively from the clinical records. We categorised male
and female patients in age, grouped as less than 60 years
old, between 60 and 70 years and older than 70 years.
Smoking history of the patients was obtained at baseline,
and patients were categorised as never-smokers, former
smokers (stop >1 year), or current smokers (stop < 1 year
or still smoking). We also looked at the number of pack
years.
Each patient had one sample in this analysis, either a
cytological or histological one. Most of the histology
samples were bronchial biopsies, with a few resection
specimens, and most of the cytology samples were EBUS-
TBNA samples. In each patient, at least 4–5 bronchial
biopsies using a 2 mm forceps (Boston) were taken or at
least 3 representative needle aspirations using a 22Ga
EBUS-TBNA needle (Olympus) until a sufficient amount
of microcores was obtained as judged by the operator.
Samples underwent fixation in 6% neutral-buffered forma-
lin, during 6–12 hours for bronchial biopsies and 8–18
hours for surgical specimens. EBUS-TBNA samples were
collected in Cytorich Red fluid, formalin fixed for 6–12
hours and paraffin-embedded in a cell block.
Immunohistochemistry (IHC) for EGFR was carried out
using a mixture of two mouse monoclonal antibodies, clone
NCL-L-EGFR-384 (1:100, Novocastra) and clone E30 (1:50,
Dako) in Dako’s EnVison FLEX Antibody Diluent (Dako)
on a Dako Autostainer Plus (Dako Denmark) according
to the manufacturer’s recommendations. EGFR expression
was reported as positive in case of membranous brown
staining in at least 10% of the cells. TTF-1 was also
immunostained using a mouse monoclonal antibody
(clone 8G7G3/1, ready-to-use, Dako), following the
same procedure as described for EGFR. Tumours were
considered TTF-1 positive in case of nuclear staining of
neoplastic cells.
For EGFR mutation analysis, one H&E slide followed
by 10 serial unstained sections (4-μM thick) and a final
H&E were prepared from the paraffin block and both
H&E sections were evaluated for the presence and
amount of tumour cells by an experienced pathologist.
After macro-dissection and deparaffinisation, the tissue
was digested overnight with proteinase K. DNA extraction
was done using the Maxwell16 FFPE tissue LEV DNA
Table 1 Clinical and pathological patient characteristics
Patients (N) EGFR mut + (N) EGFR mut + (%)
Total group 297 32 11
Gender
Female 113 26 23
Male 184 6 3
Age
<60 80 7 9
60-70 99 10 10
>70 118 15 13
Smoking
Never 40 16 40
Former 109 8 7
Current 99 7 7
Missing 49 1 -
Specimen
Cytology 84 8 10
Biopsy 213 24 11
Tumour histology
Adeno 274 31 11
NSCLC-NOS 9 1 11
Squamous 14 0 0
EGFR IHC
Positive 254 29 12
Negative 9 0 0
Missing 34 3 -
TTF-1 IHC
Positive 171 29 17
Negative 45 1 2
Missing 81 2 -
EGFR mut+: presence of activating EGFR mutation; N: number; NSCLC-NOS:
non-small cell lung cancer not otherwise specified; IHC: immunohistochemistry;
TTF-1: thyroid transcription factor 1.
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Corporation, Madison, WI) according to manufacturer’s
instructions. Mutational analysis of EGFR was performed
using the Therascreen EGFR RGQ PCR kit (produced by
Qiagen) on the LightCycler 480II instrument (Roche). The
Therascreen assay is a sequence of two techniques, ARMS
and Scorpion, to detect mutations in real-time PCRs with
a reported detection limit of 1% mutant alleles in DNA
from tumour tissue. This kit allows the detection of the
nineteen deletions between 2235 and 2258 in exon 19,
three insertions in exon 20 and the point mutations
G719A/S/C (exon 18), S768I (exon 20), T790M (exon 20),
L858R (exon 21) and L861Q (exon 21). The test has both
EU as well as FDA approval.
Ethics
This research was approved as a retrospective, non-
interventional, study by the local Institutional Review
Board of the University Hospitals KU Leuven.
Results and discussion
Clinical characteristics
From September 2010 until December 2011, a total of 297
NSCLC samples were analysed (Table 1). The population
consisted of 113 females (38%) and 184 males (62%).
The median age was 68 years (SD 11), eighty patients
were younger than 60 years, 99 were between 60 and
70 years old and 118 were older than 70 years. All
patients were Caucasians. Smoking status was known
in 248 patients, 40 (16%) were never smokers, 109
(44%) were former smokers (stop >1 year) and 99 (40%)
were current smokers.
Pathology
We examined 84 (28%) cytology samples and 213 (72%)
biopsy samples. Out of the 84 cytology specimens, 80 were
EBUS-TBNA cellblocks, and 4 were pleural cytology.
Biopsy samples were 114 bronchial biopsies, 48 archived
resection specimens, 12 lymph nodes (7 mediastinoscopy,
5 supraclavicular), 17 pleural biopsies, 11 trans-thoracic
lung tumour punctures, and 11 metastatic sites (2 bone,
2 brain, 2 liver, 4 soft tissue, 1 adrenal gland).
Two hundred and seventy-four patients had adenocar-
cinoma (92%), fourteen had squamous cell carcinoma
(5%) and nine had NSCLC-NOS (3%). EGFR immuno-
histochemistry was known for 263 patients, and was
negative (i.e. <10% membranous staining) in only 9
patients. TTF-1 status was known in 216 patients, and
was positive in 171 patients (79%).
The percentage of tumour cells was described in 293
samples. Fifty-seven samples had less than 10% tumour
cells (19%), 152 samples had between 10 and 50%
tumour cells (52%) and 84 samples had more than 50%
tumour cells (29%). There was no significant differencein percentage of tumour cells between the cytology
specimens and the biopsy samples. Out of 84 cytology
specimens, 22 had less than 10% tumour cells (26%)
versus 35 samples in 213 biopsy specimen (16%). Out
of 84 cytology specimens, 41 had between 10 and 50%
tumour cells (49%) versus 111 samples in 213 biopsy
specimens (52%). Out of 84 cytology specimens, 21 one
had more than 50% tumour cells (25%) versus 63 samples
in 213 biopsy specimens (30%) (Figure 1).
EGFR mutation test results
Activating EGFR mutations (EGFR mut+) were found
in 32 patients (11%, Table 1): twelve patients had exon
19 deletions (38%), two patients had G719A/S/C point
mutations in exon 18 (6%) and eighteen patients had
exon 21 point mutations (56%), of which fifteen L858R
Figure 1 Cumulative numbers of tumour cell content in different samples. EBUS: needle aspiration in lymph node guided by endobronchial
ultrasound guided procedure.
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insertion mutations were detected in five patients (2%).
Most mutations were found within the elderly popula-
tion. Thirteen percent mutations in patients older than
70 years, 10% mutations in patients age between 60 and
70 years and 9% activating mutations in patients younger
than 60 years.
EGFR mutation positive patients were mostly female
(81%), 26 females versus 6 males. All but one were
adenocarcinomas (97%), no activating mutations were
found in squamous cell carcinomas. EGFR-mut + were
clearly more present in never smokers (16/39, 41%) than
in current (7/97, 7%) or former smokers (8/108, 7%).
All but one EGFR-mut + patients had immunohisto-
chemistry (IHC) >50% for EGFR. This patient had 25%
IHC + for EGFR. We found no mutations in samples with
low (≤10%) EGFR-IHC. All but one EGFR-mut + patients
had TTF-1 positivity.
We found 8 EGFR-mut + in 84 cytology specimens
(10%) and 24 EGFR-mut + in 213 biopsy samples (11%).
Despite the fact that 21 out of 289 samples (7%) had low
tumour cell percentage (0-5%), we found 7 activating
mutations in these (33%). The Therascreen kit failed 4
times (1%). One failure was a bone biopsy, two had low
(5%) tumour percentage and one was a bronchial biopsy
with 25% of tumour cells. This confirms that the Therasc-
reen kit is a very sensitive test, with low test failures,
mostly when the tumour cell count was rated <5% by the
pathologist.Discussion
In the time interval September 2010 – December 2011,
we selected advanced NSCLC patients for EGFR mutation
screening in exon 18–21 by a PCR based test according to
the ESMO criteria [1]. In our 297 patients, the testing was
successful in all but four, and we detected an activating
mutation in 11%. Not surprisingly, activating mutations
were more frequently reported in women, never smokers,
and pure adenocarcinoma.
Based on this series and review of other European
findings, we believe that 9 to 12% may well be the real
frequency of activating EGFR mutations in advanced
NSCLC in Europe (Tables 2 and 3). Our frequency finding
is in line with earlier Spanish work (12% [10], and very
recent data from routine practice in e.g. the UK (9.7%
[11], 10% [12]), Lithuania (9.7% [13]), and the Netherlands
(8.4% [14]).
Some series have reported remarkably lower frequencies.
These were investigations on resection specimens, an
earlier one from Italy with a 4.5% occurrence [15], and a
recent one from Norway (6.6% [16]). In another of our
series on resection specimens, the frequency was lower as
well at 7.0% (personal communication C. Dooms). This
could be due to truly lower occurrence in early resectable
stages, although this seems less likely. It has been postu-
lated that mutations in the tyrosine kinase domain of
EGFR are early events in lung carcinogenesis, already
present in 50% of precancerous conditions such as atypical
adenomatous hyperplasia, as well as in normal lung tissue
Table 2 Demographics in European series on EGFR mutations testing
Series Year Origin N Stages Further description
Cortes-Funes et al. [10] 2005 Spain 83 Advanced Failing 1st line/TKI therapy
Marchetti et al. [15] 2005 Italy 860 Stage I-II-III Resection specimen
Rosell et al. [19] 2009 Spain 2105 Advanced -
Penzel et al. [21] 2011 Germany 1047 All -
Helland et al. [16] 2011 Norway 240 Stage I-II-III Resection specimen
Vincenten et al. [20] 2012 Netherlands 810 All -
Smits et al. [14] 2012 Netherlands 778 Advanced -
Leary et al. [12] 2012 England 144 All -
Pennycuick et al. [11] 2012 England 215 All Non-squamous NSCLC
Vaguliene et al. [13] 2012 Lithuania 103 Advanced Non-squamous NSCLC
Cadranel et al. [22] 2012 France 522 All Failing 1st line/TKI therapy
This series 2012 Belgium 297 Advanced ESMO guideline selected
N: number; TKI: tyrosine kinase inhibitor; NSCLC: non-small cell lung cancer; ESMO: European Society of Medical Oncology.
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nical factors may play a role, as resection specimens
usually don’t suffer from tissue quantity but may suffer
from tumour DNA quality. Indeed, the thoroughness of
formalin fixation (which may be less good in large
resection specimens) and the duration of storage (with
DNA degradation over time) may affect the quality of
extracted DNA and render the sample less suitable for
mutation analysis. Williams et al. illustrated that as much
as one artificial mutation per 500 bases may be recorded
in the analysis of formalin-fixed material, because of for-
malin damaging or cross-linking cytosine nucleotides [18].
Several European studies also found higher frequencies
than our study, but (unconscious) selection for testing
based on clinical factors may have played a role in these
findings. As a reminder and for comparison, in the hitherto
largest – predominantly European – study in advanced
NSCLC [2], there were 30% female patients and 14%
never-smokers. In the more recent Spanish findings inTable 3 Results in European series on EGFR mutation testing
Series Adeno (%) Female (%)
Cortes-Funes et al. [10] 51 30
Marchetti et al. [15] 44 13
Rosell et al. [19] 85 39
Penzel et al. [21] NA NA
Helland et al. [16] 59 48
Vincenten et al. [20] 65 49
Smits et al. [14] 80 46
Leary et al. [12] 67 59
Pennycuick et al. [11] NA 57
Vaguliene et al. [13] 63 25
Cadranel et al. [22] 65 32
This series 92 38the context of a randomised controlled trial, occurrence
of exon 19 or 21 mutations was 16.6% [19]. In this series,
there were 39% females, 29% never-smokers, and 75%
never- and former smokers combined. In a recent Dutch
series [20], the mutation rate was 14%, again with 49%
females. In the very large German series, no information
on gender or smoking is provided, but as the screening
program was set up for the introduction of 1st line
gefitinib in the treatment of advanced NSCLC, some
pre-selection on clinical factors may again have been in
place [21]. The series from France had a very different aim
than the studies above [22], in particular examining the
feasibility of EGFR and KRAS testing in the quite different
context of use of erlotinib for 2nd or 3rd line treatment
for all NSCLC histologies. In this group consisting of
86% never- or former smokers, the EGFR mutation rate
was 14%.
We found no EGFR mutations in our never- or light-













Table 4 Correlation between TTF-1 immunohistochemistry
and presence of EGFR activating mutation
Series EGFR mut + (N) EGFR mut- (N)
Vincenten et al. [20] NPV
TTF-1 + 105 403 96%
TTF-1 - 9 228
Leary et al. [12] NPV
TTF-1 + 15 40 100%
TTF-1 - 0 15
This series NPV
TTF-1 + 29 140 98%
TTF-1 - 1 43
Pooled results NPV
TTF- 1 + 149 583 97%
TTF-1 - 10 286
EGFR mut+: presence of activating EGFR mutation; N: number; TTF-1: thyroid
transcription factor 1; NPV: negative predictive value.
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no mutations in squamous cell carcinoma, except for
the Norwegian study, where two activating mutations
were reported in surgical resection specimens. In a recent
interesting pathology review study, all specimens with
diagnosis of EGFR/KRAS-mutant squamous cell cancer
were reassessed with modern techniques to differentiate
squamous from adenocarcinoma differentiation [23].
Detailed morphologic and immunohistochemical study
resulted in reclassification of 10 cases as adenosquamous
cancer and 5 as poorly differentiated adenocarcinoma
morphologically mimicking squamous cell cancer.
To optimize genetic testing in NSCLC, it is important
to maximize the amount of tumour cells within the
tissue sample. We investigated the tumour cell percent-
age on cytology and biopsy samples, and its effect on
PCR-based detection of EGFR mutations. There was no
significant difference between our bronchial biopsy
samples and cell blocks of the cytology samples obtained
by EBUS-TBNA. Our findings are in line with another
recent multicentre series that examined if EBUS-TBNA
cytology specimens are suitable for phenotyping and
genotyping of NSCLC. A brief report from the Netherlands
in 2010 suggested that specimens from FNA of the left
adrenal gland were suitable for EGFR mutation analysis
in 77% of the cases [24]. In a comparative study of biopsy
and fine needle aspiration samples, the latter yielded lower
DNA amounts but a comparable success rate in EGFR
mutation analysis [25]. In a recent large series, EGFR
mutation analysis was possible on cell block samples of
107/119 (90%) patients in whom it was requested [26].
ESMO guidelines advocate an EGFR TKI as the preferred
first-line treatment in NSCLC patients whose tumour
harbours an activating EGFR mutation [1]. A remaining
practical controversy is how waiting time for EGFR
mutation analysis should be balanced with delay of start of
treatment with platinum doublet chemotherapy, especially
as the overall survival with both strategies has hitherto
not been shown to be significantly different [27]. Clinical
features are related to but not sufficiently reliable to esti-
mate the presence of EGFR mutations. Consequently, a
rapid test with high negative predictive value (NPV) for
EGFR mutations is welcome. TTF-1 IHC seems to fill this
gap. Indeed, in series where this relationship is reported
(Table 4), the NPV varies between 96 and 100%, although
the NPV may be overestimated, as all series have a rather
low prevalence of EGFR mutation. As many advanced
NSCLC samples nowadays undergo IHC staining for the
differentiation between adenocarcinoma or squamous cell
carcinoma [28], TTF-1 staining is included or a little extra
with great potential for the clinician: if the TTF-1 IHC is
negative, doublet chemotherapy can be started. If an
EGFR mutation is eventually detected, the EGFR-TKI can
be given thereafter. Moreover, there is a good biologicalrationale for this high NPV, as TTF-1 expression is found
in the terminal respiratory unit (TRU) cells, where periph-
eral tumours with a non-mucinous lepidic or papillary
predominant pattern arise. Both types are known to
harbour more frequently activating EGFR mutations [29].Conclusion
Both biopsies and cell blocks of EBUS-TBNA are suitable
samples for EGFR mutation analysis when a sensitive
method such as the Therascreen EGFR RGQ PCR muta-
tion kit is used. We document an 11% frequency of EGFR
activating mutations in our Caucasian standard practice
NSCLC cohort, selected according to the ESMO consen-
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